Bright Minds Biosciences Inc

Company Profile

Bright Minds Biosciences Inc had its IPO on 2021-03-22 under the ticker symbol DRUG.

The company operates in the Healthcare sector and Biotechnology industry. Bright Minds Biosciences Inc has a staff strength of 0 employees.

Stock update

Shares of Bright Minds Biosciences Inc opened at $1.82 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.68 - $1.82, and closed at $1.73.

This is a -4.95% slip from the previous day's closing price.

A total volume of 97,019 shares were traded at the close of the day’s session.

In the last one week, shares of Bright Minds Biosciences Inc have slipped by -20.64%.

Bright Minds Biosciences Inc's Key Ratios

Bright Minds Biosciences Inc has a market cap of $10.55 million, indicating a price to book ratio of 2.7138 and a price to sales ratio of 0.

In the last 12-months Bright Minds Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Bright Minds Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bright Minds Biosciences Inc’s operating margin was 0% while its return on assets stood at -56.51% with a return of equity of -101.54%.

In Q1, Bright Minds Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Bright Minds Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bright Minds Biosciences Inc’s profitability.

Bright Minds Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.7142. Its price to sales ratio in the trailing 12-months stood at 0.

Bright Minds Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$9.99 million

Total Liabilities

$1.01 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Bright Minds Biosciences Inc ended 2024 with $9.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.99 million while shareholder equity stood at $8.95 million.

Bright Minds Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $1.01 million in other current liabilities, 33914308.00 in common stock, $-28560725.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.67 million and cash and short-term investments were $9.67 million. The company’s total short-term debt was $73,589 while long-term debt stood at $0.

Bright Minds Biosciences Inc’s total current assets stands at $9.88 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $33363.00 compared to accounts payable of $247951.00 and inventory worth $0.

In 2024, Bright Minds Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Bright Minds Biosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.73

52-Week High

$4.16

52-Week Low

$0.403

Analyst Target Price

$

Bright Minds Biosciences Inc stock is currently trading at $1.73 per share. It touched a 52-week high of $4.16 and a 52-week low of $4.16. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $2.93 and 200-day moving average was $3.26 The short ratio stood at 0.31 indicating a short percent outstanding of 0%.

Around 2385.5% of the company’s stock are held by insiders while 220.9% are held by institutions.